Hyperlipidemia treatment for mothers and newborns, which was cut off due to worsening profitability, will be re-released in two years
Jun 18, 2025
A treatment for hyperlipidemia for mothers and newborns, which had been cut off due to worsening profitability in 2023, will be re-released.
The Ministry of Health and Welfare and the Korea Health Industry Promotion Agency announced on the 18th that Boryeong Co., Ltd. was finally selected as the implementation agency of the 「Project to Support the Production of Unstable Drugs」.
The 「Project to Support the Production of Unstable Drugs」 to protect the right to national health was first launched this year, and aims to establish a stable supply chain of drugs by resuming supply and increasing production by supporting production facilities and equipment for drugs with poor domestic supply and demand.
Boryeong's 'Boryeong Questran Suspension Acid (component name cholestyramine resin, photo)' selected through a public offering as the first target of support is a bile acid-binding resin-based hyperlipidemia treatment, and it is the only treatment for hyperlipidemia in Korea that can be safely used by mothers and children in the low birth rate era.
Since the suspension of production in 2023, patients have had to purchase individually from abroad through complex procedures through the Korea Rare Essential Medicine Center.
Through this project, Boryeong plans to resume domestic production and release of Questran, which was suspended due to profitability problems in 2023, and plans to establish a stable supply system for the drug by quickly pushing for production facilities and product approval.
Jeong Eun-young, Director of the Health Industry Bureau at the Ministry of Health and Welfare, said "This is the first project to be implemented this year to establish a stable production base for essential drugs. The government will continue to expand the necessary support to provide stable supplies of medicines needed by the people through cooperation with domestic pharmaceutical companies." he said.
An official from Boryeong also said, "We are happy to continue to supply essential medicines to mothers and children through meaningful support projects" and added, "We will continue to play a leading role in the stable supply and localization of essential medicines essential for public health and do our best to practice public values.'
The Ministry of Health and Welfare and the Korea Health Industry Promotion Agency announced on the 18th that Boryeong Co., Ltd. was finally selected as the implementation agency of the 「Project to Support the Production of Unstable Drugs」.
The 「Project to Support the Production of Unstable Drugs」 to protect the right to national health was first launched this year, and aims to establish a stable supply chain of drugs by resuming supply and increasing production by supporting production facilities and equipment for drugs with poor domestic supply and demand.
|
Since the suspension of production in 2023, patients have had to purchase individually from abroad through complex procedures through the Korea Rare Essential Medicine Center.
Through this project, Boryeong plans to resume domestic production and release of Questran, which was suspended due to profitability problems in 2023, and plans to establish a stable supply system for the drug by quickly pushing for production facilities and product approval.
Jeong Eun-young, Director of the Health Industry Bureau at the Ministry of Health and Welfare, said "This is the first project to be implemented this year to establish a stable production base for essential drugs. The government will continue to expand the necessary support to provide stable supplies of medicines needed by the people through cooperation with domestic pharmaceutical companies." he said.
An official from Boryeong also said, "We are happy to continue to supply essential medicines to mothers and children through meaningful support projects" and added, "We will continue to play a leading role in the stable supply and localization of essential medicines essential for public health and do our best to practice public values.'
This article was translated by Naver AI translator.
